PROVERA 10MG TABLETS 10 MG
MEDROXYPROGESTERONE ACETATE : 10 MG · DIN 00729973 · PFIZER CANADA ULC
Health Canada status: CANCELLED POST MARKET
What is PROVERA 10MG TABLETS?
PROVERA 10MG TABLETS 10 MG contains MEDROXYPROGESTERONE ACETATE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 00729973, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 14-Nov-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PROVERA 10MG TABLETS used for?
Hormonal replacement therapy (to oppose estrogen); functional menstrual disorders; adjunctive/palliative treatment of recurrent/metastatic endometrial or breast cancer.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00729973 |
|---|---|
| Brand name | PROVERA 10MG TABLETS |
| Generic / active ingredient | MEDROXYPROGESTERONE ACETATE : 10 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G03DA02 MEDROXYPROGESTERONE |
| AHFS class | 68:32.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 14-Nov-2025 |
| Original market date | 1987-12-31 00:00:00 |
How is it administered?
Oral. HRT: 5-10 mg daily for 12-14 days. Secondary amenorrhea: 5-10 mg daily for 12-14 days. Endometrial cancer: 200-400 mg daily. Breast cancer: 400 mg daily in divided doses.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in the provided text (standard practice is 15-30°C, but text ends before section 11).
How is it supplied?
Bottles of 100 tablets for all strengths (2.5 mg, 5 mg, 10 mg).
Contraindications
Liver dysfunction; known/suspected estrogen/progestin-dependent neoplasia; breast cancer; undiagnosed abnormal genital bleeding; pregnancy; arterial/venous thromboembolic disease; vision loss.
Warnings and precautions
Increased risk of MI, stroke, invasive breast cancer, and VTE. Should be prescribed at lowest effective dose for shortest duration. May cause decrease in bone mineral density.
What can be used instead?
Other Canadian products sharing ATC code G03DA02 MEDROXYPROGESTERONE. 7 of 38 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AA-MEDROXY | 10 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02277298 |
| AA-MEDROXY | 100 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02267640 |
| AA-MEDROXY | 2.5 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02244726 |
| AA-MEDROXY | 5 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02244727 |
| TEVA-MEDROXYPROGESTERONE | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02221306 |
| TEVA-MEDROXYPROGESTERONE | 2.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02221284 |
| TEVA-MEDROXYPROGESTERONE | 5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02221292 |
| DOM-MEDROXYPROGESTERONE | 10 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02247583 |
| DOM-MEDROXYPROGESTERONE | 2.5 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02247581 |
| DOM-MEDROXYPROGESTERONE | 5 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02247582 |
Who else supplies MEDROXYPROGESTERONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MEDROXYPROGESTERONE appears in 62 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.